Drug Type Small molecule drug |
Synonyms Cenicriviroc/tropifexor, Tropifexor/Cenicriviroc + [1] |
Target |
Mechanism CCR2 antagonists(C-C chemokine receptor type 2 antagonists), CCR5 antagonists(C-C chemokine receptor type 5 antagonists), FXR agonists(Bile acid receptor FXR agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC29H25F4N3O5S |
InChIKeyVYLOOGHLKSNNEK-PIIMJCKOSA-N |
CAS Registry1383816-29-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nonalcoholic Steatohepatitis | Phase 2 | SG | 01 Aug 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | IT | 01 Aug 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | IT | 01 Aug 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | ES | 01 Aug 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | NL | 01 Aug 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | NL | 01 Aug 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | SG | 01 Aug 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | DE | 01 Aug 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | ES | 01 Aug 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | DE | 01 Aug 2016 |